MX2022015788A - Metodos y composiciones para editar el sitio de b2m en celulas b. - Google Patents

Metodos y composiciones para editar el sitio de b2m en celulas b.

Info

Publication number
MX2022015788A
MX2022015788A MX2022015788A MX2022015788A MX2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A
Authority
MX
Mexico
Prior art keywords
cells
modified
methods
killing
gene
Prior art date
Application number
MX2022015788A
Other languages
English (en)
Inventor
David J Rawlings
Richard G James
Claire Marie Stoffers
Peter J Cook
Original Assignee
Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital Dba Seattle Childrens Res Inst filed Critical Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Publication of MX2022015788A publication Critical patent/MX2022015788A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Document Processing Apparatus (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

Algunas modalidades de los métodos y composiciones que se proporcionan en este documento incluyen preparar células B modificadas. En algunas modalidades, se modifica un gen beta-2 microglobulina (B2M) endógeno en una célula B. Algunas modalidades se refieren a aumentar la resistencia de las células B modificadas a la muerte por células inmunitarias alogénicas. En algunas modalidades, el gen B2M endógeno se inactiva aumentando la resistencia de la célula B modificada a la muerte por células inmunitarias alogénicas. En algunas modalidades, se inserta un reemplazo MHC-I en un gen B2M endógeno inactivado aumentando la resistencia de la célula B modificada a la muerte por células inmunitarias alogénicas. Algunas modalidades incluyen enriquecimiento para células modificadas exitosamente.
MX2022015788A 2020-07-03 2021-06-30 Metodos y composiciones para editar el sitio de b2m en celulas b. MX2022015788A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047978P 2020-07-03 2020-07-03
US202063114131P 2020-11-16 2020-11-16
PCT/US2021/039953 WO2022006309A1 (en) 2020-07-03 2021-06-30 Methods and compositions for editing the b2m locus in b cells

Publications (1)

Publication Number Publication Date
MX2022015788A true MX2022015788A (es) 2023-02-27

Family

ID=79315579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015788A MX2022015788A (es) 2020-07-03 2021-06-30 Metodos y composiciones para editar el sitio de b2m en celulas b.

Country Status (10)

Country Link
EP (1) EP4175651A1 (es)
JP (1) JP2023532917A (es)
KR (1) KR20230035048A (es)
CN (1) CN116033910A (es)
AU (1) AU2021300358A1 (es)
BR (1) BR112022026534A2 (es)
CA (1) CA3186620A1 (es)
IL (1) IL299491A (es)
MX (1) MX2022015788A (es)
WO (1) WO2022006309A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024030857A1 (en) * 2022-08-01 2024-02-08 Idexx Laboratories, Inc. Human mouse fractional abundance assays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297018A (en) * 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Directed cleavage of cell mhc receptor
EP3645036A1 (en) * 2017-06-30 2020-05-06 Cellectis Cellular immunotherapy for repetitive administration

Also Published As

Publication number Publication date
KR20230035048A (ko) 2023-03-10
EP4175651A1 (en) 2023-05-10
CA3186620A1 (en) 2022-01-06
BR112022026534A2 (pt) 2023-04-18
IL299491A (en) 2023-02-01
JP2023532917A (ja) 2023-08-01
WO2022006309A1 (en) 2022-01-06
AU2021300358A1 (en) 2023-02-02
CN116033910A (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
Torikai et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
AU2016349280A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
MX2022015788A (es) Metodos y composiciones para editar el sitio de b2m en celulas b.
Xiong et al. Intraovarian transplantation of female germline stem cells rescue ovarian function in chemotherapy-injured ovaries
WO2007137300A3 (en) Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
WO2013104909A4 (en) Methods of preparing cells and compositions
Focosi et al. Induced pluripotent stem cells in hematology: current and future applications
MX2022001255A (es) Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales.
WO2023141472A3 (en) Engineered immune cells with enhanced potency and uses of same in immunotherapy
US20230392118A1 (en) Generation of cd4+ effector and regulatory t cells from human pluripotent stem cells
AU2015290560A1 (en) Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
MX2022009255A (es) Inmunoterapia contra cáncer usando transfusiones de celulas t alogenicas cd4+ específicas de tumor.
WO2022016166A3 (en) Differentiation of trophectoderm lineage cells from pluripotent stem cells
WO1999035245A3 (en) Methods for preparing and using immortalized human neuroendocrine cells
WO2020147272A9 (zh) 一种利用非动员外周血制备异质性造血干祖细胞的方法
MX2023000202A (es) Celulas t cd4+ de poli-donadores que expresan il-10 y usos de las mismas.
WO2023086459A3 (en) Gene editing and engineering stem cells for drug delivery
WO2023049918A3 (en) Cells expressing antigen- & sequence-specific t-cell receptors (tcrs) and methods of making the same using enforced tcr gene rearrangement
AR069884A1 (es) Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa
MX2023006878A (es) Composiciones y métodos para reducir el mhc de clase ii en una célula.
MX2022006000A (es) Composicion de cultivo de linfocitos t reguladores y su uso.
MX2021013005A (es) Metodos de fabricacion de celulas car-t alogenicas.
WO2023028469A3 (en) Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells
WO2023064284A9 (en) Derivation of hepatocytes and hematopoietic progenitors from human embryonic stem cells